Stockscreener 앱 받기
32.29
1.61%
-0.53
시간 외 거래:
32.23
-0.06
-0.19%
전일 마감가:
$32.82
열려 있는:
$32.87
하루 거래량:
3.58M
Relative Volume:
0.79
시가총액:
$13.80B
수익:
$2.26B
순이익/손실:
$1.09B
주가수익비율:
13.78
EPS:
2.3431
순현금흐름:
$2.70B
1주 성능:
-1.40%
1개월 성능:
+0.00%
6개월 성능:
+26.23%
1년 성능:
+15.03%
1일 변동 폭
$32.18
$33.11
1주일 범위
$32.18
$34.11
52주 변동 폭
$24.05
$34.20
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.29 | 13.80B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma (NASDAQ:RPRX) Upgraded by StockNews.com to Buy Rating - MarketBeat
Royalty Pharma at Bank of America 2025 Healthcare: Strategic Growth Insights - Investing.com UK
Learn to Evaluate (RPRX) using the Charts - news.stocktradersdaily.com
Royalty Pharma plc (NASDAQ:RPRX) Position Raised by Deutsche Bank AG - MarketBeat
BNP Paribas Financial Markets Makes New $41.96 Million Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Axa S.A. Acquires 138,017 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Crestline Management LP Acquires 79,532 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bridgefront Capital LLC Invests $311,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by D. E. Shaw & Co. Inc. - MarketBeat
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition - citybiz
Royalty Pharma Shareholders Approve External Manager Acquisition - marketscreener.com
Royalty Pharma shareholders approve manager acquisition - Investing.com Australia
Royalty Pharma shareholders approve manager acquisition By Investing.com - Investing.com Nigeria
Royalty Pharma’s Annual General Meeting Highlights - TipRanks
Royalty Pharma Shareholders Approve Internalization of Management with 99.9% Support, Expected to Drive Over $1.6 Billion in Cost Savings - Nasdaq
Royalty Pharma plc (RPRX) Announces Shareholder Approval of its External Manager Acquisition - StreetInsider
10,893 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Corton Capital Inc. - MarketBeat
Cutter Capital Management LP Buys 100,000 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma: Again, Guidance Raised, Buy Confirmed (NASDAQ:RPRX) - Seeking Alpha
Schonfeld Strategic Advisors LLC Raises Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Northern Trust Corp Increases Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Dimensional Fund Advisors LP Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Royalty Pharma Q1 2025 slides: double-digit growth drives raised guidance - Investing.com Nigeria
Royalty Pharma Reports Strong Q1 2025 Growth - TipRanks
ArrowMark Colorado Holdings LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q1 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma’s Earnings Call: Growth and Optimism - TipRanks
AlTi Global Inc. Buys Shares of 387,567 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Earnings call transcript: Royalty Pharma Q1 2025 misses EPS estimates By Investing.com - Investing.com Nigeria
Royalty Pharma Q1 2025 slides: double-digit growth drives raised guidance By Investing.com - Investing.com South Africa
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2025 misses EPS estimates - Investing.com
Royalty Pharma plc SEC 10-Q Report - TradingView
Royalty Pharma earnings missed by $0.66, revenue fell short of estimates - Investing.com UK
Royalty Pharma (RPRX) Projects Strong Revenue Growth for 2025 | - GuruFocus
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates - Yahoo Finance
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Royalty Pharma Reports First Quarter 2025 Results - TradingView
Royalty Pharma Reports 17% Growth in Portfolio Receipts to $839 Million and Raises 2025 Financial Guidance - Nasdaq
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
자본화:
|
볼륨(24시간):